{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014129","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.909358+00:00","generated_at":"2026-05-15T08:11:25.408717+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates","bullets":["Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.","Cash at $11.9M, down from $29.7M; adjusted EBITDA loss improved to $28.0M from $33.5M.","Received CDSCO license for PCR Pro instrument in India; expanding to South Asia with $13B addressable market.","Planning initial FDA 510(k) for flu A/B/RSV test, dropping COVID from initial submission to accelerate timeline.","Closed stock offerings raising $10.8M; engaged Maxim Group for potential SPAC for CoSara."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014129","json":"https://secwatch.observer/filing/0001493152-26-014129.json","markdown":"https://secwatch.observer/filing/0001493152-26-014129.md","text":"https://secwatch.observer/filing/0001493152-26-014129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/0001493152-26-014129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:11:25.408717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"405f49fd18e20b010ea2a69b739449cf5fca51da","claim":"Co-Diagnostics, Inc. reported full year ended December 31, 2025 results: revenue $0.6 million, net income net loss of $46.9 million, EPS $35.25 per share.","evidence_excerpt":"the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results: ● Revenue of $0.6 million, compared to $3.9 million in 2024, primarily due to lower grant revenue ● Operating expenses of $50.6 million, compared to $43.0 million in 2024, driven by a non-cash impairment","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/0001493152-26-014129-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2025"},{"label":"Revenue","value":"$0.6 million"},{"label":"Net income","value":"net loss of $46.9 million"},{"label":"EPS","value":"$35.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}